About Us

The Precision Medicine Initiative (PMI) begins a new era of medicine which aims the right treatment to the right person at the right time. Cancer is a major focus of PMI and is a disease of the genome. Therefore, understanding the knowledge of genetic changes that are in cancer cells is leading to more effective treatment strategies for each patient’s cancer. Cancer epigenetics and cancer microbiome are also recognized as important directions of cancer disease research. Besides, cancer drug research, including creation of new drugs and drug repurposing, also plays an important role in developing personized medicine. On the other hand, the integrity of variant medical data collected from next-generation sequencing, clinics, environmental and lifestyle studies meets the demand of big data analysis from four dimensions: volume, variety, velocity and veracity (4V) such that new data analysis methods are required instead of traditional database technologies. Besides, the power of traditional statistical analysis is often limited to data distribution and is difficult to deal with big data analytics. Consequently, the integration of the computing methods for precision medicine is essential to learn insights from big biomedical data for developing advanced cancer prevention and treatment. The research project integrates big data from genomics, epigenomics, microbiomics and clinical pharmacy and develops computing methods which can be applied to cancer diagnosis and treatment. In summary, this project aims to improve the quality of cancer treatment, the cure rate and patientsurvival and the outcomes can be used for the precision medicine of more diseases.

Our mission

  • Discover novel biomarkers for precision medicine: We will develop novel computation methods for analyzing DNA-Seq and RNA-Seq data and integrate them into new pipelines with state-of-the-art bioinformatics tools.
  • Support new cancer diagnosis: We will study cancer gene profiles and their relationships with epigenetic regulation targets. In addition, we will integrate different analytic methods of epigenetic studies.
    Understand the changes of the microbiota and the occurrence of cancers: We will design new lab and NGS studies simultaneously. The studies of microbime will also provide evidences of epigenetic regulations and genomic variants.
  • Discover anticancer drug candidates: We will study drug repurposing based on big data analysis of NGS data, omics databases and related life-style and medical records.
  • Develop new protocols for cancer tests: We will integrate cloud-computing and biomedical tools into a platform to support precision medicine analytics for clinical practices.